20 March 2019
Scancell Holdings Plc
("Scancell" or the "Company")
Scancell strengthens IP portfolio for immunotherapy platforms
Grant of US patent that protects Modi-1, the first clinical candidate from its Moditope® immunotherapy platform
Additional grant of European patent for anti-glycan antibody
Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, today announces that the United States Patent Office has granted a US patent that provides protection for Modi-1, the first clinical candidate from Scancell's Moditope® immunotherapy platform.
US patent number 10,233,220, entitled Anti-tumour Response to Modified Self-epitopes was granted on 19 March 2019 and claims methods of stimulating an immune response to a tumour and methods of treating cancer using peptides of Modi-1. Additional claims that aim to protect other aspects of the Moditope® platform are being pursued in the US. Grant in the US follows grant of corresponding patents in Europe, as announced last year, South Africa and Australia, and acceptance for grant in China. Counterparts to these patents are being prosecuted in other territories of importance to Scancell.
The Company also today announces the grant of European patent number 3,063,160 relating to FG88 a monoclonal antibody directed to tumour associated glycans, further strengthening the commercial positioning of Scancell's monoclonal antibody development programme.
Dr Cliff Holloway, Chief Executive Officer, Scancell, said:
"We are pleased to have been granted these two important patents for our immunotherapy platforms in the United States and Europe. This Moditope® patent provides protection for Modi-1 in the US and further endorses the novelty of Scancell's work in identifying a new class of cancer vaccine. Through the continued expansion of our intellectual property portfolio in the US and Europe, we believe we are well positioned to advance our pipeline of novel immunotherapies."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).
For Further Information:
Scancell Holdings Plc |
|
|
Dr John Chiplin, Chairman |
|
+44 (0) 20 3727 1000 |
Dr Cliff Holloway, CEO |
|
|
|
|
|
Panmure Gordon (UK) Limited (Nominated Adviser and Corporate broker) |
|
|
Freddy Crossley/Emma Earl |
|
+44 (0) 20 7886 2500 |
|
|
|
FTI Consulting Simon Conway/Natalie Garland-Collins |
|
+44 (0) 20 3727 1000 |
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.
ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They can be used as monotherapy or in combination with checkpoint inhibitors. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.
· SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.
· SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK for SCIB2.
Moditope® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4+ T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.
· Modi-1 is being developed for the treatment of solid tumours including triple negative breast cancer, ovarian cancer and head and neck cancer.
For further details, please see our website: www.scancell.co.uk
